



February 14, 2020

✓ **BSE Limited,**

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards launch of Moxifloxacin Ophthalmic Solution USP, 0.5% by the Company, for which, U.S. FDA approval was received earlier. Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of Moxeza® of Novartis which is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

R. V. Satam
For **R. V. SATAM**
COMPANY SECRETARY
(ACS - 11973)



Encl.: a/a

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin launches Moxifloxacin Ophthalmic Solution USP 0.5%

Mumbai, Baltimore, February 14, 2020: Pharma major Lupin Limited (Lupin) announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Pithampur (Unit-II) facility, India.

Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of Moxeza® of Novartis. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.

Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza®) had an annual sales of approximately USD 10 million in the U.S. (IQVIA MAT December 2019).

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupinglobal/>

| Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91-22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91-22-6640 2532

*Safe Harbor Statement

Moxeza® is a registered trademark of Novartis AG Corporation Switzerland (Novartis Group Company)